Epilepsy BDIO Infographic 01

This amazing infographic created by the Ontario Brain Institute illustrates the impact Epilepsy has on Ontarians. 


A nasal spray formulation of midazolam may diminish repeated seizures and lower the risk of generalized tonic-clonic seizures in hospitalized epilepsy patients, researchers found.


In a retrospective analysis of data from a German university epilepsy center, those given intranasal midazolam during or right after a seizure remained free of seizures longer than those not given the drug (5.83 hours versus 2.37 hours), according to Lara Kay, a doctoral candidate at Philipps University in Marburg in Germany, and colleagues.


Read full article here.

World Brain Day

July 22nd marks the second annual World Brain Day, recognized by the World Federation of Neurology. This year a special emphasis is on Epilepsy, as the World Health Organization (WHO) approved the Epilepsy Resolution, recognizing the global burden of Epilepsy. Please find links below to learn more about World Brain Day and the Epilepsy Resolution.


Introducing World Brain Day


The WHO Epilepsy Resolution>

The Ontario Brain Institute has released an in-depth report this week on Brain Disorders in Ontario. The study was a collaboration between OBI and the Institute for Clinical and Evaluative Sciences (ICES). This research is a rich source of new data on Epilepsy statistics specifically in Ontario.


Some highlights of the report include:


  • 89,867 Ontarians with Epilepsy over a 16 year period (1995-2011)
  • In Ontario, about 6000 people are diagnosed with Epilepsy every year
  • Epilepsy demographics in Ontario: 16% children, 69% adults (up to age 64) and 15% adults (65 yr +)
  • Epilepsy affects people of all ages from infants to seniors with roughly equal distribution in both males and females
  • 24% of people with Epilepsy live in the lowest income neighbourhoods and only 17% live in highest income neighbourhoods
  • Hospital care accounts for 46% of publicly-funded health care costs during

Update - July 14th, 2015




Apo-clobazam shortage is resolved. The drug identification number or DIN is 02244638.


Please note that PMS-clobazam, marketed by Pharmascience Inc, has been discontinued and is no longer available in Canada. A notice of this drug discontinuation is posted on www.drugshortages.ca. The drug identification number or DIN is 02244474.





Acetazolamide tablets are available again from AA Pharma. The drug identification number or DIN is 00545015.


Please note that Acetazolam (Valeant Canada LP) is no longer available, this product has been discontinued. A notice of this drug discontinuation is posted on www.drugshortages.ca. The drug identification number or DIN is


Website Designed and Hosted by The Social Business